RxDoctor Payments Data

Zaid Shakir, MD

Critical Care Medicine · Baltimore, MDNPI 1538450952

Payments from drug & device makers

$800in general payments, 2019–2025

Across 33 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$164
  • AstraZeneca$153
  • Sanofi$79
  • Regeneron Healthcare Solutions, Inc.$77
  • GSK$74
  • Boehringer Ingelheim$60
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$70088%
  • Education$10012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$800 in reported general payments places this provider in the 70th percentile of 231 critical care medicine providers in Maryland.

See all critical care medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$65,912
Medicare patients
295
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter270$262,623
Spiriva RespimatTiotropium Bromide25$21,533
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$21,436
Breo ElliptaFluticasone/Vilanterol24$12,816
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$9,852
Incruse ElliptaUmeclidinium Bromide15$7,421
Spiriva HandihalerTiotropium Bromide12$6,037
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,527
Albuterol Sulfate HfaAlbuterol Sulfate153$2,875
Wixela InhubFluticasone Propion/Salmeterol11$2,645
Roflumilast12$1,118
Montelukast Sodium93$1,055
Ventolin HfaAlbuterol Sulfate12$891
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$571
Fluticasone Propionate16$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$74$282,859309 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$60$31,38540 claims
AstraZenecaBreztri Aerosphere$153$21,43622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 231 critical care medicine providers in Maryland.

Other critical care medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →